Investigational drug · Phase 2
SSGJ-612
Also called: HER2-targeted antibody
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced (Unresectable) or Metastatic Solid Tumors, Metastatic Breast Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "SSGJ-612"
First trial start
2026
Jul 17, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SSGJ-612", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Metastatic Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SSGJ-612" as an intervention, largest first.
- SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid TumorsPivotal-lookingRecruiting
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07646626 · 150 participants (planned) · Start Jul 17, 2026 · Primary completion Jun 30, 2027
Drug: SSGJ-705; SSGJ-612 and 1 more · For: Locally Advanced (Unresectable) or Metastatic Solid Tumors
Sites: Hangzhou, China
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07757230 · 87 participants (planned) · Start Sep 21, 2026 · Primary completion Feb 2028
Drug: SSGJ-612 (HER2-targeted antibody); HER2-targeted ADC · For: Metastatic Breast Cancer
Sites: Guangzhou, China
Shenyang Sunshine Pharmaceutical Co., LTD.Industry
NCT07032298 · 30 participants (planned) · Start Jul 18, 2025 · Primary completion Apr 2026
Drug: SSGJ-612 · For: Advanced Malignant Tumors
Sites: Luoyang, China
Newest research
PubMed records naming it or its code names, newest first.
- Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.
Tarantino P, Valenza C, Segui E, et al. · Nat Rev Clin Oncol 2026
- Impact of time and temperature on glycation, oxidation, and functional stability of trastuzumab deruxtecan (ENHERTU®) in dextrose infusion bags.
Hindes E, Cochard V, Fourati S, et al. · Eur J Pharm Sci 2026
- Efficacy of HER2-targeted therapies in localized urothelial carcinoma: a systematic review and meta-analysis.
Suleja A, Bret D, Miszczyk M, et al. · World J Urol 2026
- Characteristics and outcomes of patients with advanced or metastatic non-small cell lung cancer harboring a HER2-activating mutation: a real-world retrospective cohort study using a US clinico-genomic database.
Le X, Chouaid C, Lopez-Rios F, et al. · Lung Cancer 2026
- Efficacy and safety of trastuzumab deruxtecan in HER2-high and HER2-low breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Hsiao SY, Lin WT, Lin CY, et al. · J Chemother 2026
- HER2-low breast cancer: a new diagnostic challenge for pathologists - insights from a single-center retrospective cohort.
Fuks J, Kalinowska A, Osowska D, et al. · Pol J Pathol 2026
Also in development for Locally Advanced (Unresectable) or Metastatic Solid Tumors
- SSGJ-705Phase 22 trials
Shenyang Sunshine Pharmaceutical Co., LTD. · Locally Advanced, Recurrent or Metastatic Malignancies, Locally Advanced (Unresectable) or Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.